Peptides are some of the most effective, research-backed compounds for healing, fat loss, immunity, and anti-aging. Here's why the FDA restricted them — and why RFK Jr. is pushing to bring them back.
Peptides are short chains of amino acids that act as signaling molecules in the body. They're not drugs in the traditional sense — they're naturally occurring compounds that tell your cells what to do. Your body already produces thousands of them. When used therapeutically, peptides can accelerate healing, burn fat, sharpen cognition, strengthen immunity, and slow the biological clock.
For years, Americans had access to these compounds through compounding pharmacies under physician supervision. Then the FDA began restricting them. The result was a wave of confusion, frustration, and a growing black market that made access less safe, not more.
Now, Robert F. Kennedy Jr. — serving as Secretary of Health and Human Services — is leading the charge to reverse these restrictions and restore Americans' access to peptide therapies. His argument is simple: these compounds work, they're safe when properly sourced, and the FDA's crackdown was driven more by pharmaceutical lobbying than genuine public health concerns.
This article covers the proven benefits of the most impactful peptides and the political battle to make them accessible again.
Peptides are chains of 2 to 50 amino acids linked by peptide bonds. They're smaller than proteins but function as highly specific biological messengers. Think of them as precision tools: each peptide targets a specific pathway in the body, triggering a defined response without the broad systemic effects (and side effects) of most pharmaceutical drugs.
The human body naturally produces peptides like insulin (which regulates blood sugar), oxytocin (which drives bonding and social behavior), and endorphins (which modulate pain). Therapeutic peptides are either synthetic versions of naturally occurring peptides or engineered sequences designed to activate specific biological pathways.
Why peptides are different from traditional drugs: Most pharmaceuticals are small molecules that interact with many receptors, causing a range of effects and side effects. Peptides are highly targeted — they bind to specific receptors and trigger specific responses. This precision is why peptide therapies tend to have significantly fewer side effects than conventional medications.
The peptide therapy market was valued at over $38 billion in 2024 and is projected to grow rapidly as more clinical data emerges. The demand isn't hype — it's driven by real results that patients and practitioners are seeing across recovery, metabolic health, immune function, and longevity.
This is where peptides first gained mainstream attention, and the evidence is compelling. Two peptides in particular — BPC-157 and TB-500 — have been extensively studied for their ability to dramatically speed up healing.
BPC-157 is a 15-amino acid peptide derived from a protein found in human gastric juice. It promotes healing by stimulating angiogenesis (new blood vessel formation), upregulating VEGF and other growth factors, and protecting the gastrointestinal lining. Published research shows accelerated healing of tendons, ligaments, muscles, nerves, and gut tissue.
TB-500 works systemically rather than locally. It upregulates actin (a critical cell-building protein), promotes cell migration to injury sites throughout the body, and reduces systemic inflammation. It's particularly studied for cardiac tissue repair, traumatic brain injury recovery, and widespread muscle injuries.
Key Insight: BPC-157 and TB-500 work through complementary mechanisms. BPC-157 builds the local repair infrastructure (blood vessels, growth factors) while TB-500 mobilizes the body's healing resources systemically. This is why they're frequently stacked together in research protocols. Read our full BPC-157 vs. TB-500 comparison.
Premium third-party tested, research-grade peptides including BPC-157, TB-500, Thymosin Alpha-1, and 40+ more. USA-based shipping with batch-specific COAs.
Shop Valor Sciences →Several peptides have demonstrated significant effects on fat metabolism, body composition, and metabolic markers — often without the harsh side effects of traditional weight loss drugs.
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that retains HGH's fat-burning properties without its growth-promoting or diabetogenic effects. Research shows it stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar or causing tissue growth.
Tesamorelin is an FDA-approved growth hormone-releasing hormone (GHRH) analog that stimulates natural GH production. It's clinically proven to reduce visceral adipose tissue (the dangerous fat around organs) by an average of 15-18% without the risks associated with direct HGH administration.
Semaglutide and tirzepatide are GLP-1 receptor agonists that have transformed the weight loss landscape. Clinical trials show average weight loss of 15-22% of body weight. These remain available as branded pharmaceuticals — but at costs of $1,000-1,500+ per month. Compounded versions were available at a fraction of the price before FDA restrictions tightened.
| Peptide | Mechanism | Key Benefit | Status |
|---|---|---|---|
| AOD-9604 | HGH fragment (lipolysis) | Fat loss without GH side effects | Restricted |
| Tesamorelin | GHRH analog | Visceral fat reduction (FDA-approved) | Available (Rx) |
| Semaglutide | GLP-1 agonist | 15-22% body weight loss | Branded only ($1,000+/mo) |
| CJC-1295 + Ipamorelin | GH secretagogue stack | Body recomp, deep sleep, recovery | Restricted |
| MOTS-c | Mitochondrial peptide | Metabolic optimization, exercise mimetic | Research compound |
The cost problem: Many of these peptides were available through compounding pharmacies for $50-200/month. Their branded pharmaceutical equivalents cost $1,000-1,500+/month. This pricing gap is at the heart of the access debate — and one of the key arguments RFK Jr. makes for restoring compounding pharmacy access.
The immune-modulating properties of certain peptides are among the most well-documented in clinical literature.
Thymosin alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland. It's approved as a pharmaceutical in over 35 countries for hepatitis B and C treatment and as an immune adjuvant. It enhances T-cell maturation, boosts natural killer cell activity, and modulates dendritic cell function. Clinical research demonstrates improved outcomes in viral infections, immunocompromised states, and as a vaccine adjuvant.
During the COVID-19 pandemic, thymosin alpha-1 was used in multiple countries as a supportive therapy for severely ill patients, with published data showing improved survival rates in ICU settings.
KPV is a tripeptide (Lysine-Proline-Valine) derived from alpha-MSH with potent anti-inflammatory properties. It inhibits NF-kB, one of the master regulators of inflammation, and has shown promise in research on inflammatory bowel disease, skin conditions, and systemic inflammation.
Selank is a synthetic analog of the naturally occurring immunopeptide tuftsin. Beyond its well-known anxiolytic and cognitive effects, selank has demonstrated immunomodulatory properties, including enhanced IL-6 expression and modulation of the immune response. It's approved as a pharmaceutical in Russia.
Peptides that cross the blood-brain barrier and directly modulate neural function represent one of the most exciting frontiers in brain health research.
Semax is a synthetic analog of ACTH (4-10) that enhances BDNF (brain-derived neurotrophic factor) expression, promotes neuroplasticity, and has demonstrated neuroprotective effects. It's approved in Russia and Ukraine for cognitive disorders and stroke recovery. Research shows improved memory, attention, and learning capacity.
Dihexa is a peptide derived from angiotensin IV that has shown remarkable cognitive effects in research — it's been described as approximately 10 million times more potent than BDNF at promoting the formation of new neural connections (synaptogenesis). While still in early research stages, its potential for neurodegenerative conditions like Alzheimer's is significant.
In addition to its immune benefits, selank acts as a potent anxiolytic without sedation or addiction potential. It modulates GABA, serotonin, and dopamine systems, producing a state of calm focus that users describe as distinct from any pharmaceutical anxiolytic. It has been compared favorably to benzodiazepines without the cognitive impairment or dependence risk.
Key Insight: The cognitive peptides highlight a critical gap in current pharmaceutical options. Existing treatments for cognitive decline, anxiety, and neuroprotection are either limited in efficacy, carry significant side effects, or create dependence. Peptides offer a fundamentally different approach — enhancing the brain's own repair and growth mechanisms rather than blunting symptoms.
The longevity research community has increasingly focused on peptides as tools for slowing or reversing biological aging markers.
Epithalon (also known as Epitalon) is a tetrapeptide that activates telomerase, the enzyme responsible for maintaining telomere length. Telomere shortening is one of the primary hallmarks of aging. Research by Professor Vladimir Khavinson demonstrated that epithalon extended lifespan in animal models and restored telomerase activity in human somatic cells. It has been used in clinical settings in Russia for over two decades.
GHK-Cu (copper peptide) is a naturally occurring tripeptide that declines significantly with age. It stimulates collagen synthesis, promotes wound healing, reduces inflammation, and has demonstrated the ability to reset gene expression patterns in aging tissue toward a younger, healthier state. Over 4,000 genes are positively modulated by GHK-Cu according to gene expression studies.
MOTS-c is a mitochondrial-derived peptide that improves metabolic function, enhances exercise capacity, and has been called an "exercise mimetic." Research shows it activates AMPK, improves insulin sensitivity, and may protect against age-related metabolic decline. It represents a new class of signaling molecules originating from mitochondrial DNA.
NAD+ (nicotinamide adenine dinucleotide) supplementation and related peptides support cellular energy production, DNA repair, and sirtuin activation — all critical pathways in the biology of aging. NAD+ levels decline approximately 50% between ages 40 and 60, contributing to the metabolic and cognitive deterioration associated with aging.
Growth hormone secretagogue peptides stimulate your body's own pituitary gland to produce more growth hormone naturally, avoiding the risks of direct HGH injection (insulin resistance, joint pain, organ growth).
The CJC-1295 and ipamorelin stack is the most widely used GH secretagogue protocol. CJC-1295 extends the duration of GH pulses, while ipamorelin triggers their release. Together, they promote deeper sleep, improved body composition, faster recovery, and better skin quality — without the supraphysiological GH levels that cause side effects with direct HGH.
Sermorelin is a GHRH analog that was FDA-approved for pediatric GH deficiency. It provides a more gentle, physiological GH elevation compared to direct HGH. It's particularly valued for its effects on sleep quality, with users reporting significantly improved deep sleep within the first few weeks of use.
GHRP-2 and GHRP-6 are growth hormone-releasing peptides that stimulate ghrelin receptors to trigger GH release. They're studied for body composition improvement, appetite regulation, and recovery enhancement. Read our full GH peptides comparison guide for detailed protocol differences.
Research-grade peptides for recovery, body composition, cognition, and longevity. Every batch independently tested for purity (98%+). Free shipping on orders over $150.
Browse All Peptides at Valor Sciences →To understand why RFK Jr. is fighting this battle, you need to understand what the FDA did and why it matters.
The FDA cited concerns about potency consistency, sterility assurance, and the absence of approved New Drug Applications (NDAs) for these peptides. They argued that without FDA-approved versions, compounded peptides posed quality and safety risks.
The irony: The FDA's stated goal was patient safety. But the practical result was the exact opposite — pushing patients away from regulated, physician-supervised compounding pharmacies and toward unregulated sources with no quality assurance. The restrictions didn't eliminate demand. They eliminated safe supply.
Robert F. Kennedy Jr. has made peptide access a central piece of his health freedom platform. His position is grounded in several core arguments:
RFK Jr. has repeatedly pointed to the body of published research supporting peptide therapies. BPC-157 alone has hundreds of published studies. Thymosin alpha-1 is approved in over 35 countries. These aren't fringe compounds — they're well-studied molecules with decades of clinical observation behind them.
Kennedy has been vocal about what he sees as regulatory capture — the FDA acting in the interests of pharmaceutical companies rather than patients. When compounded peptides are available for $100/month and their branded equivalents cost $1,500/month, the financial incentive to restrict compounding is obvious. RFK Jr. has called this "pharma protectionism disguised as safety."
A foundational principle of RFK Jr.'s approach is that informed adults, in consultation with their healthcare providers, should have the right to access therapeutic compounds with established safety records. He argues that the FDA's role should be to ensure quality and provide information — not to restrict access to compounds that work.
Kennedy has emphasized that compounding pharmacies are already subject to extensive regulation: state licensing, FDA oversight, USP compounding standards (USP 797 and 800), and regular inspections. The argument that peptides can only be safe if produced by large pharmaceutical companies doesn't hold up against the existing regulatory framework for compounding.
The bigger picture: The peptide legalization fight is part of a larger shift in how Americans think about healthcare. The old model — FDA-approved branded drugs as the only legitimate option — is being challenged by a new model that values patient choice, preventive medicine, provider autonomy, and access to safe, effective therapies regardless of whether a pharma company has filed (and paid for) a New Drug Application.
The regulatory landscape is shifting, and the outlook is more positive than it has been in years. Here's what to watch:
| Benefit Category | Key Peptides | What They Do |
|---|---|---|
| Recovery & Healing | BPC-157, TB-500 | Accelerate tissue repair, reduce inflammation, promote angiogenesis |
| Fat Loss & Metabolism | AOD-9604, Tesamorelin, Semaglutide | Enhance lipolysis, reduce visceral fat, improve metabolic markers |
| Immune Support | Thymosin Alpha-1, KPV, Selank | Boost T-cell function, modulate inflammation, enhance immune response |
| Cognitive Enhancement | Semax, Dihexa, Selank | Increase BDNF, promote neuroplasticity, protect neural tissue |
| Anti-Aging | Epithalon, GHK-Cu, MOTS-c | Extend telomeres, reset gene expression, improve mitochondrial function |
| GH Optimization | CJC-1295, Ipamorelin, Sermorelin | Stimulate natural GH production for sleep, recovery, body composition |
Dive into detailed guides for 40+ peptides with mechanisms, dosing protocols, and the latest research.
Browse All Peptide Guides →